EA200400464A1 - METHODS AND COMPOSITIONS OF NEW TRIAZINE CONNECTIONS - Google Patents

METHODS AND COMPOSITIONS OF NEW TRIAZINE CONNECTIONS

Info

Publication number
EA200400464A1
EA200400464A1 EA200400464A EA200400464A EA200400464A1 EA 200400464 A1 EA200400464 A1 EA 200400464A1 EA 200400464 A EA200400464 A EA 200400464A EA 200400464 A EA200400464 A EA 200400464A EA 200400464 A1 EA200400464 A1 EA 200400464A1
Authority
EA
Eurasian Patent Office
Prior art keywords
present
compounds
inhibit
smooth muscle
methods
Prior art date
Application number
EA200400464A
Other languages
Russian (ru)
Other versions
EA009728B1 (en
Inventor
Ричард Т. Тиммер
Кристофер У. Эликзэндер
Сиварам Пилларисетти
Удэй Саксена
Карен А. Кемпбелл
Original Assignee
Редди Ю-Эс Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Редди Ю-Эс Терапьютикс, Инк. filed Critical Редди Ю-Эс Терапьютикс, Инк.
Publication of EA200400464A1 publication Critical patent/EA200400464A1/en
Publication of EA009728B1 publication Critical patent/EA009728B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/44—One nitrogen atom with halogen atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/50—Two nitrogen atoms with a halogen atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/70—Other substituted melamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)

Abstract

Настоящее изобретение относится к способам и композициям, содержащим соединения, которые лечат физиологические состояния, возникающие из-за воспалительных ответов. В частности, настоящее изобретение направлено на соединения, которые ингибируют или блокируют вызываемую гликированным белком индукцию ассоциированного с передачей сигнала воспалительного ответа в эндотелиальных клетках. Настоящее изобретение относится к соединениям, которые ингибируют пролиферацию гладких мышц. В частности, настоящее изобретение направлено на соединения, которые ингибируют пролиферацию гладкомышечных клеток модуляцией гепарансульфатпротеогликанов, таких как перлекан. Настоящее изобретение далее относится к применению соединений для лечения сосудистых окклюзионных состояний, характеризующихся гладкомышечной пролиферацией, таких как рестеноз и атеросклероз.Отчет о международном поиске был опубликован 2003.12.11.The present invention relates to methods and compositions containing compounds that treat physiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block the glycated protein-induced induction of a signal associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit the proliferation of smooth muscle cells by modulating heparan sulfate proteoglycans, such as perlecan. The present invention further relates to the use of compounds for the treatment of vascular occlusive conditions characterized by smooth muscle proliferation, such as restenosis and atherosclerosis. The international search report was published 2003.12.11.

EA200400464A 2001-09-21 2002-09-23 Methods and compositions of novel triazine compounds EA009728B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32414701P 2001-09-21 2001-09-21
PCT/US2002/030177 WO2003024926A2 (en) 2001-09-21 2002-09-23 Methods and compositions of novel triazine compounds

Publications (2)

Publication Number Publication Date
EA200400464A1 true EA200400464A1 (en) 2005-02-24
EA009728B1 EA009728B1 (en) 2008-02-28

Family

ID=23262298

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400464A EA009728B1 (en) 2001-09-21 2002-09-23 Methods and compositions of novel triazine compounds

Country Status (16)

Country Link
EP (1) EP1436266A4 (en)
JP (1) JP2005511509A (en)
KR (1) KR20040088457A (en)
CN (1) CN1578773A (en)
BR (1) BR0212895A (en)
CA (1) CA2461074A1 (en)
EA (1) EA009728B1 (en)
IL (1) IL160984A0 (en)
IS (1) IS7190A (en)
MX (1) MXPA04002680A (en)
NO (1) NO20041187L (en)
NZ (1) NZ532349A (en)
PL (1) PL369600A1 (en)
RS (1) RS34004A (en)
WO (1) WO2003024926A2 (en)
ZA (1) ZA200403009B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112587B2 (en) 2001-09-21 2006-09-26 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7132423B2 (en) 2001-09-21 2006-11-07 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7169785B2 (en) 2001-09-21 2007-01-30 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7173032B2 (en) 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7375222B2 (en) 2002-02-05 2008-05-20 Astellas Pharma Inc. 2,4,6-Triamino-1,3,5-triazine derivative
AU2003253735A1 (en) * 2002-06-25 2004-01-06 The Center For Blood Research, Inc. Vacuolins
US20070161637A1 (en) * 2003-07-22 2007-07-12 Neurogen Corporation Substituted pyridin-2-ylamine analogues
CN1629157A (en) * 2003-12-19 2005-06-22 中国科学院上海药物研究所 Piperazinyl triazine compounds, preparation method thereof and pharmaceutical composition containing same
US7335770B2 (en) 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
US20100256160A1 (en) * 2006-11-03 2010-10-07 Nerviano Medical Sciences S.R.L. Method of administering an antitumor compound
KR101314869B1 (en) * 2010-07-29 2013-10-04 광주과학기술원 Pharmaceutical Compositions for Treating or Preventing Diabetes Comprising Triazine Compound as an Active Ingredient
JP5907986B2 (en) * 2010-11-29 2016-04-26 ガリオン ファーマシューティカルズ インコーポレイテッド Compounds as respiratory stimulants for the treatment of respiratory control disorders or respiratory control disorders
US20120295911A1 (en) 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
WO2017112951A1 (en) 2015-12-24 2017-06-29 The Regents Of The University Of California Cftr regulators and methods of use thereof
EP3672598A4 (en) 2017-08-24 2021-04-28 The Regents of The University of California Ocular pharmaceutical compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2083568C1 (en) * 1994-05-05 1997-07-10 Кубанский государственный аграрный университет Triazinecarboxylic acid salts and agent for presowing treatment of agriculture crop seeds
DE19531084A1 (en) * 1995-08-24 1997-02-27 Hoechst Schering Agrevo Gmbh 2,4-diamino-1,3,5-triazines, process for their preparation and their use as herbicides and plant growth regulators
PT1037886E (en) * 1997-12-12 2003-09-30 Abbott Lab TRIAZINE ANGIOGENESE INHIBITORS
EP0945447A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
DE60043397D1 (en) * 1999-12-28 2010-01-07 Pharmacopeia Inc CYTOKINE, PARTICULAR TNF-ALPHA, HEMMER
AU2002216650A1 (en) * 2000-10-31 2002-05-15 Lynn Bonham Triazine derivatives as lpaat-b inhibitors and uses thereof

Also Published As

Publication number Publication date
PL369600A1 (en) 2005-05-02
MXPA04002680A (en) 2004-06-18
EP1436266A2 (en) 2004-07-14
IS7190A (en) 2004-03-19
WO2003024926A3 (en) 2003-12-11
NO20041187L (en) 2004-05-19
ZA200403009B (en) 2007-12-27
IL160984A0 (en) 2004-08-31
NZ532349A (en) 2007-02-23
EA009728B1 (en) 2008-02-28
EP1436266A4 (en) 2004-12-22
BR0212895A (en) 2005-05-10
CN1578773A (en) 2005-02-09
JP2005511509A (en) 2005-04-28
CA2461074A1 (en) 2003-03-27
RS34004A (en) 2006-10-27
KR20040088457A (en) 2004-10-16
WO2003024926A2 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
EA200400464A1 (en) METHODS AND COMPOSITIONS OF NEW TRIAZINE CONNECTIONS
EA200500249A1 (en) APPLICATION OF COMPOUNDS FOR THE TREATMENT OF DISEASES MEDIATED VCAM-1
ATE450515T1 (en) ANILINOPYRIMIDENE DERIVATIVES AS IC INHIBITORS, AND RELATED COMPOSITIONS AND METHODS
PT1362047E (en) SUBSTITUTED PYRROLINE COMPOUNDS WITH INDAZOLYL AS KINASE INHIBITORS
NZ335981A (en) Ketobenzamides as calpain inhibitors
BR0314670A (en) Methods and compositions of triazine compounds
ATE225176T1 (en) USE OF SEROTONIN ANTAGONISTS (5HT3) TO TREAT FIBROMYALGIA
ATE241358T1 (en) USE OF CHOLINESTERASE INHIBITORS TO TREAT CONCENTRATION DISORDERS
PT991619E (en) INHIBITORS OF THE CELLULAR ADHESION MEDIATED BY ALFA4BETA1
ATE387444T1 (en) SUBSTITUTED PYRROLINES AS KINASE INHIBITORS
ATE273273T1 (en) PHENYLALANINE DERIVATIVES AS INHIBITORS OF ALPHA4 INTEGRINS
DE60323749D1 (en) SUBSTITUTED PYRROLINS AS KINASE INHIBITORS
ATE231837T1 (en) HYDROXAMIC ACID AND CARBOXIC ACID DERIVATIVES WITH MMP AND TNF INHIBITING EFFECTS
EA200100965A1 (en) SYNERGISM BETWEEN LOW MOLECULAR HEPARIN AND INHIBITORS AGAINSTATION OF PLATELETS THAT PROVIDES COMBINED THERAPY FOR PREVENTION AND TREATMENT OF DIFFERENT THROMBOEMBOLIC DISORDERS
FR2780729B1 (en) ZWITTERIONIC DERIVATIVES AND APPLICATION TO THE PROPERTIES OF AQUEOUS SUSPENSIONS
EA200000741A1 (en) NEW DIHYDROXYGEXANE ACID DERIVATIVES
EA200000204A1 (en) Pyrrolopyrlonone derivatives as ELASTASIS INHIBITORS NEUTROPHILS
EA200300066A1 (en) DERIVATIVES OF AMINOALCOXIBENZYL-BENZOFURANE OR BENZOTHIOPHENE, METHOD FOR THEIR PRODUCTION AND THEIR COMPOSITIONS
NO20014240D0 (en) C16-unsaturated FP-selective prostaglandin analogs
ATE184604T1 (en) NEW 2-SUBSTITUTED TRICYCLIC DERIVATIVES OF INDAN-2-MERCAPTOACETYLAMIDE USABLE AS ENCEPHALINASE INHIBITORS
EA200200948A1 (en) TREATMENT OF PSORIASIS
DE50205466D1 (en) SUBSTITUTED 2,5-DIAMIDOINDOLE AS ECE INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
DE59403966D1 (en) HYDROXYMETHYLFURAZANIC CARBONIC ACID DERIVATIVES AND THEIR USE IN TREATING CARDIOVASCULAR DISEASES
DE69429013D1 (en) USE OF DIMETICON TO TREAT THE CONSTIPATION
PT758890E (en) USE OF CATCH AGENTS, INHIBITORS OR ANTAGONISTS OF NO IN THE TREATMENT OF ENXAQUECA

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU